Free Trial

HEALTHCARE: Roche (ROSW: Aa2/AA): Announces More Targeted Pipeline

HEALTHCARE
  • WSJ interview yesterday
  • Company is cutting 25% of its pipeline following Alzheimer's and lung cancer fails
  • Focus will be on obesity and ophthalmology
  • Vabysmo selling c.CHF4bn per year was launched in 2022 but few other success stories
  • R&D spend was CHF 13.4bn last year: 23% of revenue
  • Second highest in the industry behind Merck who are trying to replace Keytruda
  • Investor Day 30th Sep will provide more details

Investor Day Link  

WSJ Link

66 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.
  • WSJ interview yesterday
  • Company is cutting 25% of its pipeline following Alzheimer's and lung cancer fails
  • Focus will be on obesity and ophthalmology
  • Vabysmo selling c.CHF4bn per year was launched in 2022 but few other success stories
  • R&D spend was CHF 13.4bn last year: 23% of revenue
  • Second highest in the industry behind Merck who are trying to replace Keytruda
  • Investor Day 30th Sep will provide more details

Investor Day Link  

WSJ Link